Crinetics pharmaceuticals, inc. (CRNX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
Operating activities:
Net loss

-50,422

-27,115

-9,157

-6,019

Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation

6,294

2,320

271

270

Depreciation and amortization

887

471

128

92

Noncash lease expense

226

-

-

-

Accretion of purchase discounts and amortization, net of premiums on investment securities

1,229

433

-

-

Other

4

-

-

-

Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other current assets

2,221

1,802

783

116

Accounts payable and accrued expenses

696

7,361

47

300

Operating lease liability

-608

-

-

-

Deferred rent

-

-261

15

5

Net cash used in operating activities

-46,381

-19,459

-9,479

-5,468

Investing activities:
Purchases of investment securities

108,136

118,399

-

-

Maturities of investment securities

150,295

-

-

-

Purchases of property and equipment

492

1,059

304

190

Net cash provided by investing activities

41,667

-119,458

-304

-190

Financing activities:
Proceeds from issuance of convertible preferred stock, net

-

63,275

11,969

-5

Proceeds from issuance of common stock, net

-

106,472

-

-

Proceeds from exercise of stock options

126

451

66

-

Repurchase of unvested shares

59

-

-

-

Repayments of borrowings under long-term debt

-

-

212

48

Net cash provided by financing activities

67

170,198

11,823

-53

Net change in cash, cash equivalents and restricted cash

-4,647

31,281

2,040

-5,711

Supplemental disclosure of cash flow information:
Cash paid for interest

-

-

8

11

Noncash investing and financing activities:
Purchase of shares pursuant to Stock Purchase Plan

735

282

-

-

Change in unvested stock liability

94

21

2

8

Amounts accrued for purchases of property and equipment

112

42

-

-

Tenant improvement allowance

-

3,304

-

-